A011801, The CompassHER2 trials (COMprehensive use of Pathologic Response ASSessment to optimize therapy in HER2 positive breast cancer): CompassHER2 Residual Disease (RD), a double blinded, phase III randomized trial of T DM1 and placebo compared with T DM1 and tucatinib (NCT 04457596)

Gender
Any

Age Group
Any

At a Glance

IRB#CIRB21-0396

Lead PhysicianOlwen Hahn

Collaborator(s)N/A

EligibilityRecruiting